Abstract
Errors in the mitotic process are thought to be one of the principal sources of the genetic instability that hallmarks cancer. Unsurprisingly, many of the proteins that regulate mitosis are aberrantly expressed in tumour cells when compared to their normal counterparts. These may represent a good source of targets for the development of novel anticancer agents. The Aurora kinases represent one such family of mitotic regulators. In recent years there has been intense interest in both understanding the role of the Aurora kinases in cell cycle regulation and also in developing small molecule inhibitors as potential novel anti-cancer drugs. With several companies now starting to take Aurora kinase inhibitors into clinical development, the time is right to review the medicinal chemistry contribution to developing the field, in particular to review the increasingly broad range of small molecule inhibitors with activity against this kinase family.
Keywords: aurora a, aurora b, cell cycle, mitosis, polyploidy, centrosome, kinase inhibition, histone h3, cytokinesis
Current Topics in Medicinal Chemistry
Title: Progress in the Development of Selective Inhibitors of Aurora Kinases
Volume: 5 Issue: 2
Author(s): Andrew Mortlock, Nicholas J. Keen, Frederic H. Jung, Nicola M. Heron, Kevin M. Foote, Robert Wilkinson and Stephen Green
Affiliation:
Keywords: aurora a, aurora b, cell cycle, mitosis, polyploidy, centrosome, kinase inhibition, histone h3, cytokinesis
Abstract: Errors in the mitotic process are thought to be one of the principal sources of the genetic instability that hallmarks cancer. Unsurprisingly, many of the proteins that regulate mitosis are aberrantly expressed in tumour cells when compared to their normal counterparts. These may represent a good source of targets for the development of novel anticancer agents. The Aurora kinases represent one such family of mitotic regulators. In recent years there has been intense interest in both understanding the role of the Aurora kinases in cell cycle regulation and also in developing small molecule inhibitors as potential novel anti-cancer drugs. With several companies now starting to take Aurora kinase inhibitors into clinical development, the time is right to review the medicinal chemistry contribution to developing the field, in particular to review the increasingly broad range of small molecule inhibitors with activity against this kinase family.
Export Options
About this article
Cite this article as:
Mortlock Andrew, Keen J. Nicholas, Jung H. Frederic, Heron M. Nicola, Foote M. Kevin, Wilkinson Robert and Green Stephen, Progress in the Development of Selective Inhibitors of Aurora Kinases, Current Topics in Medicinal Chemistry 2005; 5 (2) . https://dx.doi.org/10.2174/1568026053507651
DOI https://dx.doi.org/10.2174/1568026053507651 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond
Current Medicinal Chemistry Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy Specificity of Binding in Protein Kinases
Current Enzyme Inhibition Histone Deacetylase Inhibitors In Inflammatory Disease
Current Topics in Medicinal Chemistry World Health Organization Classification of Myelodysplastic Syndromes
Current Pharmaceutical Design Antioxidant Effects of Chalcones during the Inflammatory Response: An Overall Review
Current Medicinal Chemistry Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Advances in the Application of Podophyllotoxin Derivatives to Fight Against Multidrug-Resistant Cancer Cells
Current Topics in Medicinal Chemistry Evaluation of Direct Effect of Testosterone on NGEP and LM O1 Expression in LNCaP Prostate Cancer Cells
Current Biomarkers (Discontinued) DNA Repair in Normal and Cancer Stem Cells, with Special Reference to the Central Nervous System
Current Medicinal Chemistry Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Chemical and Genetic Engineering Strategies to Improve the Potency of Pharmaceutical Proteins and Enzymes
Current Medicinal Chemistry On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets